Adjuvant therapy with trastuzumab for early-stage breast cancer: 12 or 24 months (based on ESMO data, Vienna, october, 2012)
- 作者: Zhukova L.G1, Lichinitser M.R1
-
隶属关系:
- 期: 编号 18 (2012)
- 页面: 69-71
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280006
- ID: 280006
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Final analysis of HERA trial (median follow-up eight years) confirmed one year of trastuzumab treatment as standard of care in early-stage HER2-positive breast cancer.
全文:
参考
补充文件
